Insider Trading March 17, 2026

Cryoport Executive Discloses Stock Sale, Option and Restricted Grant Amid Mixed Quarterly Results

Chief Digital and Technology Officer sells a small stake while receiving restricted shares and options; company posts revenue beat but EPS misses in Q4 2025

By Derek Hwang CYRX
Cryoport Executive Discloses Stock Sale, Option and Restricted Grant Amid Mixed Quarterly Results
CYRX

Edward J. Zecchini, Cryoport's Chief Digital and Technology Officer, sold 2,014 shares on March 16, 2026, and on March 14 reported receipt of restricted stock rights and stock options. The company’s shares trade modestly above the sale price but are flagged by InvestingPro as overvalued; Q4 2025 results showed a revenue beat and an EPS shortfall, with the stock falling in after-hours trading.

Key Points

  • Edward J. Zecchini sold 2,014 Cryoport shares on March 16, 2026 at $8.00 per share, totaling $16,112.
  • On March 14, 2026 Zecchini was recorded as receiving 21,322 restricted stock rights (vesting annually beginning March 14, 2027) and 63,965 stock options with an $8.60 exercise price that vest monthly from April 14, 2026 and expire March 14, 2033.
  • Cryoport reported Q4 2025 revenue of $45.45 million (5.87% above expectations) but an EPS of -$0.27, missing estimates by 28.57%; shares moved lower in after-hours trading.

Edward J. Zecchini, who serves as Chief Digital and Technology Officer at Cryoport, Inc. (NASDAQ: CYRX), disclosed a sale of 2,014 shares of the company’s common stock on March 16, 2026. The transaction was completed at a per-share price of $8.00, yielding total proceeds of $16,112, according to a Form 4 filing with the Securities and Exchange Commission.

The filing also records that Zecchini acquired 21,322 shares on March 14, 2026, at a $0 acquisition price. Those shares are restricted stock rights scheduled to vest in four equal annual installments starting on March 14, 2027. On that same March 14 filing date, Zecchini received 63,965 stock options carrying an exercise price of $8.60. The option awards vest on a monthly schedule beginning April 14, 2026, and are set to expire on March 14, 2033.

Following these reported transactions, Zecchini is shown as directly owning 109,719 shares of Cryoport common stock. The sale on March 16 took place while Cryoport shares were trading at $8.37, a price level the company’s stock has reached after rising 35% over the prior 12 months but declining 13% year-to-date.

InvestingPro analysis noted in its commentary that Cryoport’s stock appears overvalued relative to its Fair Value estimate and that the name is listed among companies on the Most Overvalued list. The Form 4 disclosure and valuation commentary provide market participants with both insider activity and an outside valuation perspective.

Additional insights on Cryoport are available to InvestingPro subscribers, who have access to eight further tips about CYRX, including content described as relating to the company’s financial health and market positioning.


In a recent corporate filing of operating results, Cryoport reported fourth-quarter 2025 financials that present a mixed picture. Revenue for the period was $45.45 million, ahead of analysts’ consensus of $42.93 million, constituting a 5.87% revenue surprise. Earnings per share, however, came in at -$0.27 versus an expected -$0.21, representing a 28.57% miss on EPS.

Despite the top-line outperformance, the company’s shares declined in aftermarket trading following the release of the quarterly report. The set of developments - insider transactions, valuation commentary, and the mixed quarter - collectively frame the current disclosure environment for Cryoport as it continues to report results and file required insider reports.

All transaction dates, share counts, prices, vesting schedules and expiry dates cited above reflect the details listed in the SEC Form 4 and the company’s published quarterly results.

Risks

  • Insider sales and grants can generate investor scrutiny and short-term share price volatility - affecting equity investors and market liquidity.
  • Valuation concerns noted by InvestingPro, which lists the stock as appearing overvalued relative to Fair Value, introduce uncertainty for prospective buyers and portfolio managers assessing CYRX.
  • Mixed quarterly results - revenue above expectations but EPS below forecasts - create uncertainty around near-term profitability and operational execution, relevant to shareholders and analysts following corporate earnings.

More from Insider Trading

Reddit Director Increases Stake With $1.38 Million Purchase Mar 17, 2026 MP Materials General Counsel Sells $834,979 in Stock as Company Posts Mixed Q4 Results Mar 17, 2026 Columbia Banking System Tops Q4 Estimates; Analysts Lift Targets, Dividend Declared Mar 17, 2026 Delek US EVP Sells Nearly $500k in Stock as Company Posts Mixed Q4 Results Mar 17, 2026 Bloom Energy CCO Sells $3.08M in Shares Amid Strong Market Run for Stock Mar 17, 2026